Clinical, Cosmetic and Investigational Dermatology最新文献

{"title":"Oral and Topical Spironolactone in Adult Female Acne: A Narrative Review Comparing Systemic and Local Approaches.","authors":"Magdalena Łyko, Aleksandra Złotowska, Alina Jankowska-Konsur","doi":"10.2147/CCID.S630692","DOIUrl":"https://doi.org/10.2147/CCID.S630692","url":null,"abstract":"<p><strong>Background: </strong>Adult female acne (AFA) affects 12-45% of women over 25 years of age and is frequently resistant to conventional therapies. The antiandrogenic properties of spironolactone have positioned it as a promising non-antibiotic alternative. While oral spironolactone has been increasingly studied, its topical formulation remains comparatively underexplored, and recent evidence syntheses have generally pooled both routes of administration rather than comparing them within a framework specific to AFA.</p><p><strong>Objective: </strong>This narrative review synthesizes and critically compares the available evidence on the efficacy, safety, and practical considerations of oral versus topical spironolactone in AFA.</p><p><strong>Methods: </strong>A literature search was conducted in PubMed and Google Scholar on 1 September 2025, using search terms combining adult female acne with spironolactone. Original clinical studies-randomized controlled trials, observational studies, and case series-were included. Preclinical studies, non-English-language articles, and non-original data were excluded.</p><p><strong>Results: </strong>Oral spironolactone (50-200 mg/day) consistently demonstrates significant reductions in inflammatory and non-inflammatory lesion counts and improves acne-specific quality of life. Head-to-head trials indicate comparable or superior efficacy relative to doxycycline, with longer treatment persistence than oral antibiotics. Topical spironolactone (2-5%) reduces comedones, papules, and pustules with minimal systemic absorption, suggesting a potential option for patients who are not candidates for systemic therapy. However, the evidence base for topical formulations remains limited by small sample sizes and heterogeneous study designs, and is derived largely from small mixed-sex or non-AFA cohorts and from pharmacokinetic studies in healthy volunteers; its applicability to AFA is therefore currently indirect and extrapolated.</p><p><strong>Conclusion: </strong>Oral spironolactone is supported by robust evidence as an effective non-antibiotic option for AFA and is suitable for moderate-to-severe disease, whereas topical spironolactone appears promising but remains supported by limited and partly indirect evidence, derived largely from small and heterogeneous studies, and may be appropriate for mild-to-moderate acne or when systemic therapy is contraindicated. Because no head-to-head trial has compared the two routes, the comparison presented here is necessarily indirect. Future research should prioritize head-to-head comparisons of both routes and standardization of topical formulations.</p>","PeriodicalId":10447,"journal":{"name":"Clinical, Cosmetic and Investigational Dermatology","volume":"19 ","pages":"630692"},"PeriodicalIF":2.5,"publicationDate":"2026-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13626010/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149105074","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Osimertinib, a Trigger of Subacute Cutaneous Lupus Erythematosus: Three-Patient Case Series and Literature Review.","authors":"Joanna Nowiszewska, Mateusz Polaczek, Carolyn Szwed, Leszek Blicharz, Aleksandra Piórek, Lidia Rudnicka, Joanna Czuwara","doi":"10.2147/CCID.S616408","DOIUrl":"10.2147/CCID.S616408","url":null,"abstract":"<p><strong>Background: </strong>Osimertinib, a third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), is the standard first-line therapy for EGFR-mutant non-small cell lung cancer (NSCLC). While acneiform rash, pruritus, xerosis and paronychia are well-recognized cutaneous adverse events of EGFR-TKIs, drug-induced subacute cutaneous lupus erythematosus (DI-SCLE) is an emerging and under-recognized complication that may be misdiagnosed as eczema, psoriasis or drug allergic reaction, potentially leading to inappropriate management and permanent discontinuation of life-prolonging targeted therapy.</p><p><strong>Case presentations: </strong>We report three female patients (aged 55-80 years) with EGFR-mutant NSCLC who developed DI-SCLE during osimertinib therapy, presenting with characteristic annular and polycyclic erythematous plaques in a photodistributed location 3-17 months after treatment initiation. Histopathological examination revealed irregularly thin epidermis with dyskeratotic keratinocytes, interface lymphocytic infiltrate and vacuolar degeneration of the basal layer in all cases corresponding to subacute cutaneous lupus erythematosus. Direct immunofluorescence demonstrated immunoglobulin and complement deposition along the dermoepidermal junction in two of three patients (positive lupus band test). All patients were managed with systemic corticosteroids and antimalarials (hydroxychloroquine or chloroquine) additionally used in two patients. This approach enabled continuation or resumption of osimertinib.</p><p><strong>Conclusion: </strong>These three cases establish osimertinib-induced SCLE as a recognizable clinical entity. Early dermatologic referral with skin biopsy and direct immunofluorescence is essential for accurate diagnosis, enabling appropriate immunosuppressive management while preserving access to life-prolonging targeted therapy. Early recognition therefore allows appropriate dermatologic management while maintaining effective oncologic treatment.</p>","PeriodicalId":10447,"journal":{"name":"Clinical, Cosmetic and Investigational Dermatology","volume":"19 ","pages":"616408"},"PeriodicalIF":2.5,"publicationDate":"2026-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13621944/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149080017","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Refractory Adult-Onset Localized Cutaneous Langerhans Cell Histiocytosis Successfully Treated with Surgical Intervention: Case Report.","authors":"Yaru Tan, Junyou Zheng, Yabo Yao, Beilei Xu, Hao Song, Yan Wang, Wenbo Bu, Zhiwen Wang","doi":"10.2147/CCID.S634614","DOIUrl":"https://doi.org/10.2147/CCID.S634614","url":null,"abstract":"<p><p>Langerhans cell histiocytosis (LCH) is a rare clonal proliferative disorder that frequently mimics common inflammatory dermatoses, often resulting in delayed diagnosis. We report a highly deceptive clinical presentation. A 36-year-old man presented with a five-year history of painful, refractory ulcerated plaques on his bilateral groins. Previous empirical therapies failed completely. A targeted skin biopsy eventually revealed classic atypical Langerhans cells with reniform nuclei, demonstrating striking immunohistochemical positivity for CD1a and CD207. Comprehensive systemic investigations confirmed isolated cutaneous involvement. Although subsequent trials of systemic agents-including thalidomide, methotrexate, and upadacitinib-were poorly tolerated and offered limited benefit, surgical excision ultimately achieved complete resolution. The patient has not presented recurrence at 18-month follow-up. This case highlights the critical necessity of an early biopsy for chronic intertriginous ulcers. Furthermore, it demonstrates that surgical management serves as a safe and durable definitive strategy for recalcitrant, localized cutaneous LCH.</p>","PeriodicalId":10447,"journal":{"name":"Clinical, Cosmetic and Investigational Dermatology","volume":"19 ","pages":"634614"},"PeriodicalIF":2.5,"publicationDate":"2026-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13623540/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149105100","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Burden, Trends, Associated Diseases and Predictions of Alopecia Areata in China, Japan, South Korea, and Globally: A GBD 2023 Analysis.","authors":"Yue Pan, Xianghui Li, Gao Wei, Zhijian Yao, Zhuren Ruan","doi":"10.2147/CCID.S646030","DOIUrl":"10.2147/CCID.S646030","url":null,"abstract":"<p><strong>Background: </strong>Alopecia areata (AA) causes non-scarring hair loss and substantial psychosocial burden, yet its trends, comorbidities, and future burden in East Asia remain underexplored.</p><p><strong>Methods: </strong>Global Burden of Disease(GBD) Study 2023 data from 1990-2023 were analyzed for the world, China, Japan, and South Korea. Age-standardized incidence (ASIR), prevalence (ASPR), and disability-adjusted life-year (DALY) rates were assessed by region, sex, and age. Joinpoint regression quantified temporal trends. Ecological correlations with associated diseases and socio-demographic Index (SDI) were examined. Burden through 2046 was projected using United Nations population estimates.</p><p><strong>Results: </strong>In 2023, Japan and South Korea had higher ASIR and ASPR than China and global averages. Females bore greater burden; incidence peaked in young-to-middle-aged adults. Global age-standardized rates(ASRs) declined (1990-2023), while rates remained stable in China and persistently high in Japan and South Korea. AA correlated with atopic dermatitis, iron deficiency anemia, and thyroid disorders. Higher SDI was associated with lower incidence in Japan, South Korea, and globally, but not in China. Substantial cases are projected through 2046.</p><p><strong>Conclusion: </strong>AA burden varies by region, sex, and age, and will continue to be a major public health issue. Clinicians should be particularly attentive to women and East Asian patients. While the etiology appears multifactorial, causality remains to be confirmed at the individual level. Nevertheless, these findings support more vigilant screening and tailored prevention in high-risk East Asian populations.</p>","PeriodicalId":10447,"journal":{"name":"Clinical, Cosmetic and Investigational Dermatology","volume":"19 ","pages":"646030"},"PeriodicalIF":2.5,"publicationDate":"2026-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13618623/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149073698","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Topical Calcineurin Inhibitors in Rosacea: Potential Benefit in Selected Clinical Settings and Risk of Rosaceiform Dermatitis.","authors":"Tingwei Liu, Xiaoqi Meng, Nuoran Chen, Wanqing Yang, Dansheng Li, Yang Xu","doi":"10.2147/CCID.S630416","DOIUrl":"10.2147/CCID.S630416","url":null,"abstract":"<p><p>Rosacea is a chronic inflammatory skin disorder characterized by persistent erythema, flushing, papules, pustules, and telangiectasia, predominantly affecting the central face. Topical calcineurin inhibitors (TCIs), including tacrolimus and pimecrolimus, are approved for atopic dermatitis(AD) but have also been used off-label in rosacea and other facial inflammatory dermatoses. Evidence for their use in rosacea is limited and mixed. Some small uncontrolled studies have reported clinical improvement, particularly with pimecrolimus. In contrast, rosaceiform dermatitis has been reported during treatment with both tacrolimus and pimecrolimus, including cases with increased <i>Demodex</i> density. These reports highlight the need to distinguish primary rosacea from steroid-induced rosacea-like dermatitis(SIRD) and other rosaceiform eruptions associated with topical therapies. Tacrolimus and pimecrolimus have also been studied in different clinical settings, and the available evidence does not support treating them as interchangeable. Current guidelines and consensus statements provide no consistent recommendation for TCI use in primary rosacea. This review summarizes the clinical evidence for the potential benefits and adverse effects of TCIs in rosacea and discusses their possible role in selected clinical settings.</p>","PeriodicalId":10447,"journal":{"name":"Clinical, Cosmetic and Investigational Dermatology","volume":"19 ","pages":"630416"},"PeriodicalIF":2.5,"publicationDate":"2026-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13620306/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149079980","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Myxoid Onychomatricoma with Unusual CD99 Expression: A Report of a Rare Case and Literature Review.","authors":"Xingwei Zou, Zhongping Tang, Xueyu Zhang, Yongqiong Deng","doi":"10.2147/CCID.S642035","DOIUrl":"10.2147/CCID.S642035","url":null,"abstract":"<p><p>Onychomatricoma (OM) is a rare, benign fibroepithelial tumor originating from the nail matrix, with different clinical and histological variants documented in existing studies. Myxoid OM is an even rarer subtype, characterized by a prominent fibromyxoid component in histopathology. We report a case of a 34-year-old male patient presenting with clinical manifestations consistent with typical OM. Histopathological examination revealed a biphasic tumor composed of an epithelial component and a prominent myxoid stroma, suggesting a diagnosis of myxoid OM. Notably, the tumor exhibited diffuse CD99 positivity, an extremely rare finding in OM. Histopathologically, myxoid OM shows considerable morphological overlap with superficial acral fibromyxoma (SAFM). Our case illustrates that CD99 positivity cannot serve as an absolute criterion to exclude OM; cautious interpretation of this marker is required to avoid diagnostic pitfalls in the differential diagnosis of these two entities. This case expands the immunophenotypic spectrum of myxoid OM and offers a valuable reference for its differential diagnosis. Furthermore, we include and provide a descriptive review to summarize the clinicopathological features and key differential diagnostic considerations of OM, with a focus on diagnostic pitfalls arising from rare histological variants and atypical immunophenotypes, to facilitate accurate differential diagnosis of subungual tumors.</p>","PeriodicalId":10447,"journal":{"name":"Clinical, Cosmetic and Investigational Dermatology","volume":"19 ","pages":"642035"},"PeriodicalIF":2.5,"publicationDate":"2026-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13616141/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149069350","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unsaturated Fatty Acids and the Risk of Acne: A Mendelian Randomization Study the Impact of Unsaturated Fatty Acids on Acne.","authors":"Wanglin Zhang, Tiantian Wang, Rong Zhang, Xiaotian Ji, Jianfeng Wang, Yubo Zhang, Yang Meng","doi":"10.2147/CCID.S607359","DOIUrl":"10.2147/CCID.S607359","url":null,"abstract":"<p><strong>Background: </strong>The investigation into unsaturated fatty acids has spanned an extensive period; however, the evidence supporting their therapeutic efficacy in treating acne remains inconclusive. Previous research has predominantly focused on omega-3 and omega-6 fatty acids, with limited exploration of the roles played by monounsaturated fatty acids and specific unsaturated fatty acids such as docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA).</p><p><strong>Methods: </strong>To more comprehensively assess the impacts of diverse unsaturated fatty acids and their subcomponents, we employed Mendelian randomization methodology. Our primary analytical approach was inverse variance weighting (IVW), supplemented by a series of sensitivity analyses to enhance the robustness of our findings. Given the potential for overlapping single nucleotide polymorphisms (SNPs) among the various unsaturated fatty acids under investigation, we incorporated multivariate Mendelian randomization to reduce the risk of false positives. Additionally, Bayesian weighted Mendelian randomization was utilized to confirm the consistency of our results.</p><p><strong>Results: </strong>Univariate Mendelian randomization indicated that omega-3 and DHA were inversely associated with acne risk, while the omega-6 to omega-3 ratio showed a positive correlation with acne risk. Multivariate Mendelian randomization revealed that only DHA demonstrated a positive association with acne risk, a finding supported by Bayesian weighted Mendelian randomization.</p><p><strong>Conclusion: </strong>Collectively, these results suggest that our data primarily support the protective influence of DHA against acne.</p>","PeriodicalId":10447,"journal":{"name":"Clinical, Cosmetic and Investigational Dermatology","volume":"19 ","pages":"607359"},"PeriodicalIF":2.5,"publicationDate":"2026-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13615744/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149058954","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Potential Causal Association Between Plasma Lipidomes and Keloid: Analysis from a Two-Sample Mendelian Randomization.","authors":"Tao Ma, Haibin Wu, Song Gong","doi":"10.2147/CCID.S629011","DOIUrl":"10.2147/CCID.S629011","url":null,"abstract":"<p><strong>Background: </strong>Keloid formation is a multifaceted biological response to skin injury characterized by fibrous connective tissue, and functional and aesthetic impairments. Recent research highlights the role of plasma lipidomes in various diseases, yet their specific relationship with keloid formation has not been extensively studied.</p><p><strong>Objective: </strong>This study aims to elucidate the causal relationship between plasma lipidomes and keloid formation using a two-sample Mendelian randomization (MR) approach.</p><p><strong>Methods: </strong>Firstly, we employed a two-sample MR framework, utilizing genetic instrumental variables (IVs) derived from large-scale genome-wide association studies (GWAS). The exposure data comprised 179 plasma lipid species measured in 7174 individuals of European ancestry, while outcome data on keloids were sourced from a GWAS involving 436,200 individuals. IVs were selected using a significance threshold of P < 1×10^-5 and linkage disequilibrium criteria, yielding 4507 independent single-nucleotide polymorphisms (SNPs). Causal effect estimates were calculated using multiple MR methods, and sensitivity analyses were conducted to evaluate the robustness of the findings.</p><p><strong>Results: </strong>The analysis suggested a significant association between elevated levels of Phosphatidylcholine (O-16:0_16:0) and increased risk of keloid formation (OR 1.399, 95% CI 1.166-1.678, p-value < 0.001) by Inverse-variance weighted (IVW). Sensitivity analyses confirmed the absence of heterogeneity and significant horizontal pleiotropy, reinforcing the validity of the causal inference.</p><p><strong>Conclusion: </strong>Our findings indicate that specific lipid species, particularly Phosphatidylcholine, may be associated with an increased risk of keloid formation, highlighting a potential role of lipid metabolism in keloid pathophysiology.</p>","PeriodicalId":10447,"journal":{"name":"Clinical, Cosmetic and Investigational Dermatology","volume":"19 ","pages":"629011"},"PeriodicalIF":2.5,"publicationDate":"2026-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13614313/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149058866","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identification and Preliminary mRNA Validation of Key Genes Associated with Tolerogenic Dendritic Cells in Keloid Based on Transcriptome Data.","authors":"Zhongyang Sun, Xuejie Gao, Rongxin Ren, Hongyi Zhao","doi":"10.2147/CCID.S618045","DOIUrl":"10.2147/CCID.S618045","url":null,"abstract":"<p><strong>Purpose: </strong>Keloid is a cutaneous fibrotic disorder characterized by excessive fibrous tissue proliferation during wound healing. Tolerogenic dendritic cells (tolDCs) may participate in keloid immunopathology, but the related molecular signatures remain unclear. This study aimed to identify candidate tolDC-associated genes in keloid by integrating tolDC-related transcriptomic profiles with keloid transcriptomic datasets.</p><p><strong>Patients and methods: </strong>Public keloid and tolDC transcriptome datasets were analyzed. Candidate genes were screened by intersecting keloid differentially expressed genes (DEGs) with tolDC-related DEGs. Key genes were selected using protein-protein interaction analysis, machine learning algorithms, expression comparison, and ROC analysis. An ANN model based on the selected genes was constructed and validated. Enrichment analysis, subcellular localization, immune infiltration analysis, regulatory network construction, drug prediction, and molecular docking were performed to explore their potential biological relevance. The expression of key genes was preliminarily validated at the mRNA level in clinical samples by RT-qPCR.</p><p><strong>Results: </strong>A total of 2,182 keloid DEGs and 3,541 tolDC-related genes were intersected, and CCL20 and NLRC4 were identified as candidate key genes. The ANN model showed potential diagnostic value for distinguishing keloid from control samples. CCL20 and NLRC4 were mainly localized in the cytoplasm and were associated with pathways including Reactome antimicrobial peptide signaling. Immune infiltration analysis showed associations with six immune cell types, including eosinophils and memory B cells. Regulatory network analysis identified 31 miRNAs potentially targeting these genes, and drug prediction suggested associations with 79 chemical compounds. RT-qPCR analysis in clinical samples supported the bioinformatics findings at the mRNA level.</p><p><strong>Conclusion: </strong>This study identified CCL20 and NLRC4 as candidate tolDC-associated genes in keloid. These genes may provide candidate diagnostic biomarkers and hypotheses for future immunomodulatory therapeutic targets in keloid.</p>","PeriodicalId":10447,"journal":{"name":"Clinical, Cosmetic and Investigational Dermatology","volume":"19 ","pages":"618045"},"PeriodicalIF":2.5,"publicationDate":"2026-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13614326/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149058886","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Integrative Transcriptomic and Genetic Analyses Identify CDC20 as a Potential Biomarker Associated with Cell Cycle and Immune-Inflammatory Processes in Psoriasis.","authors":"Lingyi Yang, Wenshen Mo, Gang Wang, Xiaowei Wu","doi":"10.2147/CCID.S636697","DOIUrl":"10.2147/CCID.S636697","url":null,"abstract":"<p><strong>Objective: </strong>To identify psoriasis-associated candidate genes and regulatory features via integrated transcriptomic, immune and genetic analyses, and validate them in an imiquimod-induced psoriasis-like murine model.</p><p><strong>Methods: </strong>Public GEO transcriptomic datasets were integrated after batch-effect correction. We performed differential expression, WGCNA, machine-learning-based feature selection and diagnostic modelling, CIBERSORT immune infiltration estimation, transcription-factor regulation, drug enrichment, colocalization and SMR analyses. In-vivo histological and Western blot validation was conducted in mice.</p><p><strong>Results: </strong>We obtained 767 candidate genes enriched in cell-cycle and immune-inflammatory pathways. The Lasso-XGBoost model (AUC = 0.923) yielded 11 candidate genes that well separate psoriasis patients from healthy controls. Drug enrichment identified Lucanthone. SMR revealed consistent expression-genetic directionality for LYN and IL1RN. Notably, the 11 machine-learning-derived signature genes mainly mark psoriasis disease activity and differ from the SMR-identified genetically supported causal genes LYN and IL1RN. Increased CDC20, CCNB1 and CDK1 protein levels were confirmed in mouse lesional skin.</p><p><strong>Conclusion: </strong>This study suggests that CDC20 may serve as a potential biomarker for cell cycle and immune-inflammatory processes in psoriasis, providing a basis for further mechanistic and translational studies.</p>","PeriodicalId":10447,"journal":{"name":"Clinical, Cosmetic and Investigational Dermatology","volume":"19 ","pages":"636697"},"PeriodicalIF":2.5,"publicationDate":"2026-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13614442/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149058943","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}